Skip to content

Released Aug 7, 2018, after the close

10-Q filed Aug 7, 2018, 38 days after period end · 0001193125-18-241301

Q2 2018 · 10-Q
Revenue$19.89M+662,933.3% vs Q2 2017+98.9% vs Q1 2018
Net Income-$33.66MN/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.60N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$34,332,000N/M
Operating Cash Flowderived-$37,628,000N/M
Free Cash Flowderived-$38,025,000—
Margins · derived
Operating margin-172.6%+991560.7 pt vs Q2 2017
Net margin-169.2%+979397.5 pt vs Q2 2017

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2018Q2 2017Q2 2016Q2 2015
Revenue$19.89M$3.00K$59.00K$150.00K
Net Income-$33.66M-$29.39M-$30.16M-$32.70M
EPS Diluted-$0.60-$0.64-$0.84-$0.92

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR